Tolerância e resposta imune à vacina tríplice acelular do adulto (dTpa) em adolescentes infectados pelo vírus da imunodeficiência humana (HIV)
Autor(a) principal: | |
---|---|
Data de Publicação: | 2016 |
Tipo de documento: | Dissertação |
Idioma: | por |
Título da fonte: | Repositório Institucional da UNIFESP |
Texto Completo: | https://sucupira.capes.gov.br/sucupira/public/consultas/coleta/trabalhoConclusao/viewTrabalhoConclusao.jsf?popup=true&id_trabalho=4244441 http://repositorio.unifesp.br/handle/11600/47548 |
Resumo: | Background: Despite the decay in morbidity and mortality among HIV-infected children and adolescents, they still have a higher susceptibility to infectious diseases and a reduced immune response to vaccination. However, knowledge on immune response to vaccine antigens is scarce in HIV-infected adolescents. Objectives: To evaluate the tolerability, antibody persistence and the humoral and cellular response after Tdap in HIV-infected and in healthy adolescents, in comparison to healthy adolescents. Methodology: This was a controlled non-blind clinical trial with HIV-infected adolescents (HIV, n=30) and healthy controls (CONTROL, n=30) who had received primary vaccination scheme (3 doses) and at least one booster dose of tetanus diphtheria whole cell pertussis vaccine and who had at least a 3 year-interval since the last vaccine dose. Individuals from HIV group had to have at least 200 CD4+ T cells/mm3. Pregnancy was an exclusion criterion for both groups. One Tdap was administered and adolescents filled in a form to report adverse events. Three blood samples were collected: immediately bofore vaccination (day 0) and after 14 (day 14) e 28 days (day 28). Lymphocyte subset immunophenotyping with flow cytometry was performed on day 0. Humoral immunity to tetanus, diphtheria and pertussis toxin was assessed by ELISA. In vitro culture was performed with whole blood stimulated with tetanus toxoid, Bordetella pertussis or medium. Supernatants were collected after 7 days, kept frozen and subsequently assessed for cytokines secretion by xMAP-Luminex platform. This project was approved by the Ethics Committee and all patients and guardians signed a written informed consent. Results: Mean age of HIV and CONTROL groups were 17.9 e 17.1 years, respectively. Postimmunization adverse events were similar in the two groups, but for pain, which was more intense in CONTROL group (20.0%x66.7%, p<0.001). On day 0, the percentage of susceptible individuals was comparable in both groups, although HIV group had higher tetanus antibody levels than CONTROL group. On days 14 and 28, both groups had an increase in tetanus, diphtheria and pertussis toxin antibodies. However, for diphtheria, HIV group had lower antibody levels on days 14 (p=0.001) and 28 (p=<0.001). Three individuals did not attain diphtheria protective antibody levels, and one of them did not seroconvert to tetanus as well. For pertussis, the percentage of individuals who seroconverted was significantly lower in HIV group on days 14 (p=0.002) and 28 (p=0.001). For the cellular immune response to tetanus, both groups built a Th2 (IL-4, IL-5 and IL-13) and Th1 (IFN-?) response. In HIV group, IL-17a levels increased; however, cytokine levels in supernatant were lower in HIV than in CONTROL group. In the cellular immune response to pertussis, HIV group had a statistically significant increase in Th1 (IFN-?) and Th17 (IL-17a) cytokines, while CONTROL group had an increase of Th2 (IL-4) cytokine. Conclusions: Antibody persistence for diphtheria and pertussis after primary vaccination scheme was similar in both groups. For tetanus, antibody levels were lowere in CONTROL than in HIV group, although the proportion of immune individuals was similar between groups. Both groups tolerated well Tdap. HIV and CONTROL groups presented an adequate humoral imune response to tetanus and diphtheria; however, HIV group had a lower seroconversion rate for pertussis than CONTROL group. Both HIV and CONTROL groups presented a cellular immune response to tetanus and pertussis. However, lower cytokine levels were observed in HIV group before and after Tdap, suggestive of a less efficient cellular response when compared to CONTROL group. |
id |
UFSP_79891a65ad9113c653546710a03972a6 |
---|---|
oai_identifier_str |
oai:repositorio.unifesp.br/:11600/47548 |
network_acronym_str |
UFSP |
network_name_str |
Repositório Institucional da UNIFESP |
repository_id_str |
3465 |
spelling |
Tolerância e resposta imune à vacina tríplice acelular do adulto (dTpa) em adolescentes infectados pelo vírus da imunodeficiência humana (HIV)Tolerance and immune response to tetanus diphtheria acellular pertussis vaccine (Tdpa) in adolescents infected with the human immunodeficiency virus (HIV)PertussisTetanusDiphteriaHIVImmunizationCoquelucheTétanoDifteriaHIVImunizaçãoBackground: Despite the decay in morbidity and mortality among HIV-infected children and adolescents, they still have a higher susceptibility to infectious diseases and a reduced immune response to vaccination. However, knowledge on immune response to vaccine antigens is scarce in HIV-infected adolescents. Objectives: To evaluate the tolerability, antibody persistence and the humoral and cellular response after Tdap in HIV-infected and in healthy adolescents, in comparison to healthy adolescents. Methodology: This was a controlled non-blind clinical trial with HIV-infected adolescents (HIV, n=30) and healthy controls (CONTROL, n=30) who had received primary vaccination scheme (3 doses) and at least one booster dose of tetanus diphtheria whole cell pertussis vaccine and who had at least a 3 year-interval since the last vaccine dose. Individuals from HIV group had to have at least 200 CD4+ T cells/mm3. Pregnancy was an exclusion criterion for both groups. One Tdap was administered and adolescents filled in a form to report adverse events. Three blood samples were collected: immediately bofore vaccination (day 0) and after 14 (day 14) e 28 days (day 28). Lymphocyte subset immunophenotyping with flow cytometry was performed on day 0. Humoral immunity to tetanus, diphtheria and pertussis toxin was assessed by ELISA. In vitro culture was performed with whole blood stimulated with tetanus toxoid, Bordetella pertussis or medium. Supernatants were collected after 7 days, kept frozen and subsequently assessed for cytokines secretion by xMAP-Luminex platform. This project was approved by the Ethics Committee and all patients and guardians signed a written informed consent. Results: Mean age of HIV and CONTROL groups were 17.9 e 17.1 years, respectively. Postimmunization adverse events were similar in the two groups, but for pain, which was more intense in CONTROL group (20.0%x66.7%, p<0.001). On day 0, the percentage of susceptible individuals was comparable in both groups, although HIV group had higher tetanus antibody levels than CONTROL group. On days 14 and 28, both groups had an increase in tetanus, diphtheria and pertussis toxin antibodies. However, for diphtheria, HIV group had lower antibody levels on days 14 (p=0.001) and 28 (p=<0.001). Three individuals did not attain diphtheria protective antibody levels, and one of them did not seroconvert to tetanus as well. For pertussis, the percentage of individuals who seroconverted was significantly lower in HIV group on days 14 (p=0.002) and 28 (p=0.001). For the cellular immune response to tetanus, both groups built a Th2 (IL-4, IL-5 and IL-13) and Th1 (IFN-?) response. In HIV group, IL-17a levels increased; however, cytokine levels in supernatant were lower in HIV than in CONTROL group. In the cellular immune response to pertussis, HIV group had a statistically significant increase in Th1 (IFN-?) and Th17 (IL-17a) cytokines, while CONTROL group had an increase of Th2 (IL-4) cytokine. Conclusions: Antibody persistence for diphtheria and pertussis after primary vaccination scheme was similar in both groups. For tetanus, antibody levels were lowere in CONTROL than in HIV group, although the proportion of immune individuals was similar between groups. Both groups tolerated well Tdap. HIV and CONTROL groups presented an adequate humoral imune response to tetanus and diphtheria; however, HIV group had a lower seroconversion rate for pertussis than CONTROL group. Both HIV and CONTROL groups presented a cellular immune response to tetanus and pertussis. However, lower cytokine levels were observed in HIV group before and after Tdap, suggestive of a less efficient cellular response when compared to CONTROL group.Introdução: Apesar da queda da morbimortalidade de crianças e adolescentes infectados pelo HIV, ainda persiste uma maior suscetibilidade a doenças infecciosas e um comprometimento da resposta à vacinação nesta população. Entretanto, pouco se conhece sobre a resposta imunológica a vacinas na população adolescente infectada pelo HIV. Objetivos: Avaliar a tolerabilidade, persistência de anticorpos e a resposta imune humoral e celular após dose de reforço com a vacina dTpa em adolescentes infectados com HIV e compará-la com a resposta de adolescentes saudáveis. Metodologia: Em ensaio clínico controlado não cego, foram incluídos adolescentes infectados com HIV (n=30) e adolescentes saudáveis (CONTROLE, n=30) que receberam vacinação primária (3 doses) e pelo menos um reforço com a vacina tríplice bacteriana de células inteiras (DTP) na infância e tinham pelo menos 3 anos do último reforço. Os indivíduos do grupo HIV deveriam apresentar células T CD4+>200 células/mm3. Gravidez era critério de exclusão nos dois grupos. Uma dose da vacina dTpa foi administrada e os adolescentes preencheram uma ficha para registro de eventos adversos. Foram também realizadas 3 coletas de sangue: imediatamente antes da vacina (dia 0) e após 14 (dia 14) e 28 dias (dia 28). Foi realizada imunofenotipagem de linfócitos por citometria de fluxo no dia 0. A avaliação da imunidade humoral para tétano, difteria e toxina pertussis foi feita por ensaio imunoenzimático. A imunidade celular foi realizada para toxoide tetânico e B. pertussis após estimulação in vitro de sangue total e dosagem de citocinas em sobrenadante por X-MAP. O projeto foi aprovado pelo Comitê de Ética em Pesquisa e todos os pacientes ou seus responsáveis assinaram o termo de consentimento e assentimento livre esclarecido. Resultados: Os grupos HIV e CONTROLE apresentaram média de idade de 17,9 e 17,1 anos, respectivamente. Os eventos adversos relatados foram semelhantes nos dois grupos, com exceção de dor local, que foi mais intensa no grupo CONTROLE (20,0%x66,7%, p<0,001). No dia 0, a porcentagem de indivíduos suscetíveis nos grupos foi comparável, embora o grupo HIV apresentasse níveis de anticorpos para tétano mais elevados que o grupo CONTROLE. No dia 14 e dia 28, os 2 grupos responderam com elevação dos níveis de anticorpos para tétano, difteria e coqueluche. Entretanto, para difteria, o grupo HIV manteve níveis de anticorpos mais baixos nos dias 14 (p=0,001) e 28 (p=<0,001). Três indivíduos não atingiram níveis protetores para difteria, um dos quais também não soroconverteu para tétano. Para coqueluche, a proporção de indivíduos que soroconverteu foi significantemente menor no grupo HIV no dia 14 (p=0,002) e dia 28 (p=0,001). Na avaliação da imunidade celular para tétano, ambos os grupos montaram uma resposta Th2 (IL-4, IL-5 e IL-13) e Th1 (IFN-?). No grupo HIV, observamos um incremento da IL-17a, entretanto os níveis de citocinas em sobrenadante foram mais baixos quando comparados aos do grupo CONTROLE. Já na avaliação da imunidade celular para coqueluche, o grupo HIV teve um incremento estatisticamente significante para citocinas do tipo Th1 (IFN-?) e Th17 (IL-17a), enquanto o grupo CONTROLE, somente do tipo Th2 (IL-4). Conclusões: A persistência dos anticorpos para difteria e coqueluche foi semelhante nos grupos HIV e CONTROLE; para o tétano, o grupo CONTROLE apresentou níveis de anticorpos significantemente mais baixos embora a proporção de indivíduos suscetíveis tenha sido semelhante. A vacina dTpa apresentou boa tolerabilidade nos dois grupos de adolescentes. Os grupos HIV e CONTROLE apresentaram uma boa resposta imune humoral para tétano, difteria, porém para coqueluche o grupo HIV demonstrou uma soroconversão inferior ao grupo CONTROLE. Tanto o grupo HIV quanto o CONTROLE apresentaram uma resposta imune celular para tétano e para coqueluche. Entretanto, níveis mais baixos de diversas citocinas foram observados no grupo HIV antes e após a vacina dTpa, sugerindo uma resposta celular menos eficiente, quando comparada à do grupo CONTROLEDados abertos - Sucupira - Teses e dissertações (2013 a 2016)Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES)FAPESP: 2013/218531Universidade Federal de São Paulo (UNIFESP)Pinto, Maria Isabel de Moraes [UNIFESP]http://lattes.cnpq.br/0967318191677557http://lattes.cnpq.br/2373504893502131Universidade Federal de São Paulo (UNIFESP)Spina, Fernanda Garcia [UNIFESP]2018-07-30T11:44:43Z2018-07-30T11:44:43Z2016-12-16info:eu-repo/semantics/masterThesisinfo:eu-repo/semantics/publishedVersion87 f.application/pdfhttps://sucupira.capes.gov.br/sucupira/public/consultas/coleta/trabalhoConclusao/viewTrabalhoConclusao.jsf?popup=true&id_trabalho=4244441SPINA, Fernanda Garcia. Tolerância e resposta imune à vacina tríplice acelular do adulto (dTpa) em adolescentes infectados pelo vírus da imunodeficiência humana (HIV). 2016. 87 f. Dissertação (Mestrado em Pediatria e Ciências Aplicadas à Pediatria) - Escola Paulista de Medicina, Universidade Federal de São Paulo (UNIFESP), São Paulo, 2016.Fernanda Garcia Spina - PDF A.pdfhttp://repositorio.unifesp.br/handle/11600/47548porSão Pauloinfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da UNIFESPinstname:Universidade Federal de São Paulo (UNIFESP)instacron:UNIFESP2024-08-01T17:13:56Zoai:repositorio.unifesp.br/:11600/47548Repositório InstitucionalPUBhttp://www.repositorio.unifesp.br/oai/requestbiblioteca.csp@unifesp.bropendoar:34652024-08-01T17:13:56Repositório Institucional da UNIFESP - Universidade Federal de São Paulo (UNIFESP)false |
dc.title.none.fl_str_mv |
Tolerância e resposta imune à vacina tríplice acelular do adulto (dTpa) em adolescentes infectados pelo vírus da imunodeficiência humana (HIV) Tolerance and immune response to tetanus diphtheria acellular pertussis vaccine (Tdpa) in adolescents infected with the human immunodeficiency virus (HIV) |
title |
Tolerância e resposta imune à vacina tríplice acelular do adulto (dTpa) em adolescentes infectados pelo vírus da imunodeficiência humana (HIV) |
spellingShingle |
Tolerância e resposta imune à vacina tríplice acelular do adulto (dTpa) em adolescentes infectados pelo vírus da imunodeficiência humana (HIV) Spina, Fernanda Garcia [UNIFESP] Pertussis Tetanus Diphteria HIV Immunization Coqueluche Tétano Difteria HIV Imunização |
title_short |
Tolerância e resposta imune à vacina tríplice acelular do adulto (dTpa) em adolescentes infectados pelo vírus da imunodeficiência humana (HIV) |
title_full |
Tolerância e resposta imune à vacina tríplice acelular do adulto (dTpa) em adolescentes infectados pelo vírus da imunodeficiência humana (HIV) |
title_fullStr |
Tolerância e resposta imune à vacina tríplice acelular do adulto (dTpa) em adolescentes infectados pelo vírus da imunodeficiência humana (HIV) |
title_full_unstemmed |
Tolerância e resposta imune à vacina tríplice acelular do adulto (dTpa) em adolescentes infectados pelo vírus da imunodeficiência humana (HIV) |
title_sort |
Tolerância e resposta imune à vacina tríplice acelular do adulto (dTpa) em adolescentes infectados pelo vírus da imunodeficiência humana (HIV) |
author |
Spina, Fernanda Garcia [UNIFESP] |
author_facet |
Spina, Fernanda Garcia [UNIFESP] |
author_role |
author |
dc.contributor.none.fl_str_mv |
Pinto, Maria Isabel de Moraes [UNIFESP] http://lattes.cnpq.br/0967318191677557 http://lattes.cnpq.br/2373504893502131 Universidade Federal de São Paulo (UNIFESP) |
dc.contributor.author.fl_str_mv |
Spina, Fernanda Garcia [UNIFESP] |
dc.subject.por.fl_str_mv |
Pertussis Tetanus Diphteria HIV Immunization Coqueluche Tétano Difteria HIV Imunização |
topic |
Pertussis Tetanus Diphteria HIV Immunization Coqueluche Tétano Difteria HIV Imunização |
description |
Background: Despite the decay in morbidity and mortality among HIV-infected children and adolescents, they still have a higher susceptibility to infectious diseases and a reduced immune response to vaccination. However, knowledge on immune response to vaccine antigens is scarce in HIV-infected adolescents. Objectives: To evaluate the tolerability, antibody persistence and the humoral and cellular response after Tdap in HIV-infected and in healthy adolescents, in comparison to healthy adolescents. Methodology: This was a controlled non-blind clinical trial with HIV-infected adolescents (HIV, n=30) and healthy controls (CONTROL, n=30) who had received primary vaccination scheme (3 doses) and at least one booster dose of tetanus diphtheria whole cell pertussis vaccine and who had at least a 3 year-interval since the last vaccine dose. Individuals from HIV group had to have at least 200 CD4+ T cells/mm3. Pregnancy was an exclusion criterion for both groups. One Tdap was administered and adolescents filled in a form to report adverse events. Three blood samples were collected: immediately bofore vaccination (day 0) and after 14 (day 14) e 28 days (day 28). Lymphocyte subset immunophenotyping with flow cytometry was performed on day 0. Humoral immunity to tetanus, diphtheria and pertussis toxin was assessed by ELISA. In vitro culture was performed with whole blood stimulated with tetanus toxoid, Bordetella pertussis or medium. Supernatants were collected after 7 days, kept frozen and subsequently assessed for cytokines secretion by xMAP-Luminex platform. This project was approved by the Ethics Committee and all patients and guardians signed a written informed consent. Results: Mean age of HIV and CONTROL groups were 17.9 e 17.1 years, respectively. Postimmunization adverse events were similar in the two groups, but for pain, which was more intense in CONTROL group (20.0%x66.7%, p<0.001). On day 0, the percentage of susceptible individuals was comparable in both groups, although HIV group had higher tetanus antibody levels than CONTROL group. On days 14 and 28, both groups had an increase in tetanus, diphtheria and pertussis toxin antibodies. However, for diphtheria, HIV group had lower antibody levels on days 14 (p=0.001) and 28 (p=<0.001). Three individuals did not attain diphtheria protective antibody levels, and one of them did not seroconvert to tetanus as well. For pertussis, the percentage of individuals who seroconverted was significantly lower in HIV group on days 14 (p=0.002) and 28 (p=0.001). For the cellular immune response to tetanus, both groups built a Th2 (IL-4, IL-5 and IL-13) and Th1 (IFN-?) response. In HIV group, IL-17a levels increased; however, cytokine levels in supernatant were lower in HIV than in CONTROL group. In the cellular immune response to pertussis, HIV group had a statistically significant increase in Th1 (IFN-?) and Th17 (IL-17a) cytokines, while CONTROL group had an increase of Th2 (IL-4) cytokine. Conclusions: Antibody persistence for diphtheria and pertussis after primary vaccination scheme was similar in both groups. For tetanus, antibody levels were lowere in CONTROL than in HIV group, although the proportion of immune individuals was similar between groups. Both groups tolerated well Tdap. HIV and CONTROL groups presented an adequate humoral imune response to tetanus and diphtheria; however, HIV group had a lower seroconversion rate for pertussis than CONTROL group. Both HIV and CONTROL groups presented a cellular immune response to tetanus and pertussis. However, lower cytokine levels were observed in HIV group before and after Tdap, suggestive of a less efficient cellular response when compared to CONTROL group. |
publishDate |
2016 |
dc.date.none.fl_str_mv |
2016-12-16 2018-07-30T11:44:43Z 2018-07-30T11:44:43Z |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/masterThesis |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
format |
masterThesis |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
https://sucupira.capes.gov.br/sucupira/public/consultas/coleta/trabalhoConclusao/viewTrabalhoConclusao.jsf?popup=true&id_trabalho=4244441 SPINA, Fernanda Garcia. Tolerância e resposta imune à vacina tríplice acelular do adulto (dTpa) em adolescentes infectados pelo vírus da imunodeficiência humana (HIV). 2016. 87 f. Dissertação (Mestrado em Pediatria e Ciências Aplicadas à Pediatria) - Escola Paulista de Medicina, Universidade Federal de São Paulo (UNIFESP), São Paulo, 2016. Fernanda Garcia Spina - PDF A.pdf http://repositorio.unifesp.br/handle/11600/47548 |
url |
https://sucupira.capes.gov.br/sucupira/public/consultas/coleta/trabalhoConclusao/viewTrabalhoConclusao.jsf?popup=true&id_trabalho=4244441 http://repositorio.unifesp.br/handle/11600/47548 |
identifier_str_mv |
SPINA, Fernanda Garcia. Tolerância e resposta imune à vacina tríplice acelular do adulto (dTpa) em adolescentes infectados pelo vírus da imunodeficiência humana (HIV). 2016. 87 f. Dissertação (Mestrado em Pediatria e Ciências Aplicadas à Pediatria) - Escola Paulista de Medicina, Universidade Federal de São Paulo (UNIFESP), São Paulo, 2016. Fernanda Garcia Spina - PDF A.pdf |
dc.language.iso.fl_str_mv |
por |
language |
por |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
87 f. application/pdf |
dc.coverage.none.fl_str_mv |
São Paulo |
dc.publisher.none.fl_str_mv |
Universidade Federal de São Paulo (UNIFESP) |
publisher.none.fl_str_mv |
Universidade Federal de São Paulo (UNIFESP) |
dc.source.none.fl_str_mv |
reponame:Repositório Institucional da UNIFESP instname:Universidade Federal de São Paulo (UNIFESP) instacron:UNIFESP |
instname_str |
Universidade Federal de São Paulo (UNIFESP) |
instacron_str |
UNIFESP |
institution |
UNIFESP |
reponame_str |
Repositório Institucional da UNIFESP |
collection |
Repositório Institucional da UNIFESP |
repository.name.fl_str_mv |
Repositório Institucional da UNIFESP - Universidade Federal de São Paulo (UNIFESP) |
repository.mail.fl_str_mv |
biblioteca.csp@unifesp.br |
_version_ |
1814268428576358400 |